 |
PDBsum entry 1gs4
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Androgen receptor
|
PDB id
|
|
|
|
1gs4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Androgen receptor
|
 |
|
Title:
|
 |
Structural basis for the glucocorticoid response in a mutant human androgen receptor (arccr) derived from an androgen-independent prostate cancer
|
|
Structure:
|
 |
Androgen receptor. Chain: a. Fragment: ligand-binding domain, residues 670-917. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008
|
|
Resolution:
|
 |
|
1.95Å
|
R-factor:
|
0.205
|
R-free:
|
0.285
|
|
|
Authors:
|
 |
P.M.Matias,M.A.Carrondo,R.Coelho,M.Thomaz,X.-Y.Zhao,A.Wegg,K.Crusius, U.Egner,P.Donner
|
|
Key ref:
|
 |
P.M.Matias
et al.
(2002).
Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer.
J Med Chem,
45,
1439-1446.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
27-Dec-01
|
Release date:
|
16-Jan-03
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P10275
(ANDR_HUMAN) -
Androgen receptor from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
920 a.a.
244 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 2 residue positions (black
crosses)
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Med Chem
45:1439-1446
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer.
|
|
P.M.Matias,
M.A.Carrondo,
R.Coelho,
M.Thomaz,
X.Y.Zhao,
A.Wegg,
K.Crusius,
U.Egner,
P.Donner.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The crystal structure of a mutant androgen receptor (AR) ligand-binding domain
(LBD) in complex with the agonist 9alpha-fluorocortisol has been determined at
1.95 A resolution. This mutant AR contains two mutations (L701H and T877A) and
was previously reported as a high-affinity cortisol/cortisone responsive AR
(AR(ccr)) isolated from the androgen-independent human prostate cancer cell
lines MDA PCa 2a and 2b (Zhao et al. Nature Med. 2000, 6, 703-6). The
three-dimensional structure of the AR(ccr) LBD complexed with
9alpha-fluorocortisol shows the typical conformation of an agonist-bound nuclear
receptor in which helix 12 is precisely positioned as a "lid" for the
ligand-binding pocket. Binding of 9alpha-fluorocortisol to the AR(ccr) involves
favorable hydrogen bond patterns on the C17 and C21 substituents of the ligand
due to the mutations at 701 and 877 in the AR(ccr). Our studies provide the
first structural explanation for the glucocorticoid activation of AR(ccr), which
is important for the development of new therapeutic treatments for
androgen-independent prostate cancer.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
T.B.Knudsen,
K.A.Houck,
N.S.Sipes,
A.V.Singh,
R.S.Judson,
M.T.Martin,
A.Weissman,
N.C.Kleinstreuer,
H.M.Mortensen,
D.M.Reif,
J.R.Rabinowitz,
R.W.Setzer,
A.M.Richard,
D.J.Dix,
and
R.J.Kavlock
(2011).
Activity profiles of 309 ToxCastâ„¢ chemicals evaluated across 292 biochemical targets.
|
| |
Toxicology,
282,
1.
|
 |
|
|
|
|
 |
J.P.Bergerat,
and
J.Céraline
(2009).
Pleiotropic functional properties of androgen receptor mutants in prostate cancer.
|
| |
Hum Mutat,
30,
145-157.
|
 |
|
|
|
|
 |
Y.K.Lau,
M.K.Chadha,
A.Litwin,
and
D.L.Trump
(2008).
A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
|
| |
J Hematol Oncol,
1,
21.
|
 |
|
|
|
|
 |
E.B.Askew,
R.T.Gampe,
T.B.Stanley,
J.L.Faggart,
and
E.M.Wilson
(2007).
Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.
|
| |
J Biol Chem,
282,
25801-25816.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Robzyk,
H.Oen,
G.Buchanan,
L.M.Butler,
W.D.Tilley,
A.K.Mandal,
N.Rosen,
and
A.J.Caplan
(2007).
Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor.
|
| |
Mol Cell Endocrinol,
268,
67-74.
|
 |
|
|
|
|
 |
V.Nahoum,
and
W.Bourguet
(2007).
Androgen and estrogen receptors: potential of crystallography in the fight against cancer.
|
| |
Int J Biochem Cell Biol,
39,
1280-1287.
|
 |
|
|
|
|
 |
W.H.Bisson,
A.V.Cheltsov,
N.Bruey-Sedano,
B.Lin,
J.Chen,
N.Goldberger,
L.T.May,
A.Christopoulos,
J.T.Dalton,
P.M.Sexton,
X.K.Zhang,
and
R.Abagyan
(2007).
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
|
| |
Proc Natl Acad Sci U S A,
104,
11927-11932.
|
 |
|
|
|
|
 |
B.He,
R.T.Gampe,
A.T.Hnat,
J.L.Faggart,
J.T.Minges,
F.S.French,
and
E.M.Wilson
(2006).
Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity.
|
| |
J Biol Chem,
281,
6648-6663.
|
 |
|
|
|
|
 |
D.J.Hwang,
J.Yang,
H.Xu,
I.M.Rakov,
M.L.Mohler,
J.T.Dalton,
and
D.D.Miller
(2006).
Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer.
|
| |
Bioorg Med Chem,
14,
6525-6538.
|
 |
|
|
|
|
 |
K.Pereira de Jésus-Tran,
P.L.Côté,
L.Cantin,
J.Blanchet,
F.Labrie,
and
R.Breton
(2006).
Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity.
|
| |
Protein Sci,
15,
987-999.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.E.Bohl,
D.D.Miller,
J.Chen,
C.E.Bell,
and
J.T.Dalton
(2005).
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.
|
| |
J Biol Chem,
280,
37747-37754.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.E.Bohl,
W.Gao,
D.D.Miller,
C.E.Bell,
and
J.T.Dalton
(2005).
Structural basis for antagonism and resistance of bicalutamide in prostate cancer.
|
| |
Proc Natl Acad Sci U S A,
102,
6201-6206.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
F.Schaufele,
X.Carbonell,
M.Guerbadot,
S.Borngraeber,
M.S.Chapman,
A.A.Ma,
J.N.Miner,
and
M.I.Diamond
(2005).
The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions.
|
| |
Proc Natl Acad Sci U S A,
102,
9802-9807.
|
 |
|
|
|
|
 |
W.Gao,
C.E.Bohl,
and
J.T.Dalton
(2005).
Chemistry and structural biology of androgen receptor.
|
| |
Chem Rev,
105,
3352-3370.
|
 |
|
|
|
|
 |
G.Buchanan,
P.S.Craft,
M.Yang,
A.Cheong,
J.Prescott,
L.Jia,
G.A.Coetzee,
and
W.D.Tilley
(2004).
PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer.
|
| |
Prostate,
60,
352-366.
|
 |
|
|
|
|
 |
G.Liao,
L.Y.Chen,
A.Zhang,
A.Godavarthy,
F.Xia,
J.C.Ghosh,
H.Li,
and
J.D.Chen
(2003).
Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT.
|
| |
J Biol Chem,
278,
5052-5061.
|
 |
|
|
|
|
 |
H.Tamura,
H.Yoshikawa,
K.W.Gaido,
S.M.Ross,
R.K.DeLisle,
W.J.Welsh,
and
A.M.Richard
(2003).
Interaction of organophosphate pesticides and related compounds with the androgen receptor.
|
| |
Environ Health Perspect,
111,
545-552.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |